Test

TKTKTKTKTKTK

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Utilizing 100-Percent Domestic Additive Manufacturing: Q&A with Kyle Smith

ByMike Hollan,Kyle Smith

June 25th 2026

Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

ByMike Hollan

June 24th 2026

Eli Lilly and Abbisko Announce Drug Development Collaboration

ByMike Hollan

June 24th 2026

How 3D Printing Speeds Up Drug Production

ByMike Hollan,Kyle Smith

June 24th 2026

The intersection of the 340B program with the Inflation Reduction Act (IRA) introduces new complexities in pricing strategy. Credit: Stock.Adobe.com/Yevg45.

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

ByPartha Anbil

June 24th 2026

Test

Related Content

Utilizing 100-Percent Domestic Additive Manufacturing: Q&A with Kyle Smith

Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

Eli Lilly and Abbisko Announce Drug Development Collaboration

How 3D Printing Speeds Up Drug Production

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

Trending on PharmExec

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

How 3D Printing Speeds Up Drug Production

Eli Lilly and Abbisko Announce Drug Development Collaboration

Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

FDA Pilot Targets Faster Early-Stage Drug Trial Starts